NCT02999932 (POSDOT) is a NA clinical trial of SpO2 directed oxygen therapy in Critical Illness, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT02999932?

Interventions in NCT02999932: SpO2 directed oxygen therapy.

What condition does NCT02999932 study?

NCT02999932 studies Critical Illness.

Is NCT02999932 still recruiting?

NCT02999932 is currently terminated. Last updated 11 July 2023.

Last reviewed 2023-07-11 · How we verify

NCT02999932: POSDOT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peripheral Oxygen Saturation (SpO2) Directed Oxygen Therapy

Terminated NA Last updated 11 July 2023

What this trial tests

NA trial testing SpO2 directed oxygen therapy in Critical Illness in 1,706 participants. Terminated before completion.

Timeline

1 May 2019

Primary endpoint
1 May 2022

29 May 2022

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1,706
Start date	1 May 2019
Primary completion	1 May 2022
Estimated completion	29 May 2022
Sites	13 locations across China

Drugs / interventions tested

SpO2 directed oxygen therapy

Conditions studied

Critical Illness — all drugs for Critical Illness →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

18 and older, any sex, with Critical Illness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigators hypothesized that a relative low SpO2 directed oxygen therapy would reduced the mortality in patients staying longer than 72 hours in ICUs.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Higher versus lower fractions of inspired oxygen or targets of arterial oxygenation for adults admitted to the intensive care unit.
Klitgaard TL, Schjørring OL, Nielsen FM, Meyhoff CS, et al · · 2023 · cited 27× · PMID 37700687 · DOI 10.1002/14651858.cd012631.pub3
Low versus high pulse oxygen saturation directed oxygen therapy in critically ill patients: a randomized controlled pilot study.
Yang X, Shang Y, Yuan S. · · 2019 · cited 22× · PMID 31737308 · DOI 10.21037/jtd.2019.09.66
Low versus high peripheral oxygen saturation directed oxygen therapy in critically ill patients: a multicenter randomized controlled trial.
Yang X, Gao X, Zheng X, Zhao X, et al · · 2025 · PMID 39968493 · DOI 10.1002/mco2.70098

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02999932 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 11 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02999932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing